Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

被引:899
作者
Wang, TH
Niu, GL
Kortylewski, M
Burdelya, L
Shain, K
Zhang, SM
Bhattacharya, R
Gabrilovich, D
Heller, R
Coppola, D
Dalton, W
Jove, R
Pardoll, D [1 ]
Yu, H
机构
[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Immunol Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Clin Invest Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nm976
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although tumor progression involves processes such as tissue invasion that can activate inflammatory responses, the immune system largely ignores or tolerates disseminated cancers. The mechanisms that block initiation of immune responses during cancer development are poorly understood. We report here that constitutive activation of Stat-3, a common oncogenic signaling pathway, suppresses tumor expression of proinflammatory mediators. Blocking Stat-3 in tumor cells increases expression of proinflammatory cytokines and chemokines that activate innate immunity and dendritic cells, leading to tumor-specific T-cell responses. In addition, constitutive Stat-3 activity induces production of pleiotropic factors that inhibit dendritic cell functional maturation. Tumor-derived factors inhibit dendritic cell maturation through Stat-3 activation in progenitor cells. Thus, inhibition of antitumor immunity involves a cascade of Stat-3 activation propagating from tumor to dendritic cells. We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system.
引用
收藏
页码:48 / 54
页数:7
相关论文
共 38 条
[1]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[2]   VEGF differentially activates STAT3 in microvascular endothelial cells [J].
Bartoli, M ;
Platt, DH ;
Lemtalsi, T ;
Gu, XL ;
Brooks, SE ;
Marrero, MB ;
Caldwell, RB .
FASEB JOURNAL, 2003, 17 (09) :1562-+
[3]   Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma [J].
Bloom, MB ;
PerryLalley, D ;
Robbins, PF ;
Li, Y ;
ElGamil, M ;
Rosenberg, SA ;
Yang, JC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) :453-459
[4]   Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis [J].
Bowman, T ;
Broome, MA ;
Sinibaldi, D ;
Wharton, W ;
Pledger, WJ ;
Sedivy, JM ;
Irby, R ;
Yeatman, T ;
Courtneidge, SA ;
Jove, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) :7319-7324
[5]   STATs in oncogenesis [J].
Bowman, T ;
Garcia, R ;
Turkson, J ;
Jove, R .
ONCOGENE, 2000, 19 (21) :2474-2488
[6]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[7]  
Brossart P, 2000, CANCER RES, V60, P4485
[8]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[9]   A critical role for stat3 signaling in immune tolerance [J].
Cheng, FD ;
Wang, HW ;
Cuenca, A ;
Huang, M ;
Ghansah, T ;
Brayer, J ;
Kerr, WG ;
Takeda, K ;
Akira, S ;
Schoenberger, SP ;
Yu, H ;
Jove, R ;
Sotomayor, EM .
IMMUNITY, 2003, 19 (03) :425-436
[10]  
Davidson JM, 1992, INFLAMMATION BASIC P, P809